Home | Welcome to Contract Pharma   
Last Updated Wednesday, May 27 2015


Akorn Completes VersaPharm Acquisition

Published August 12, 2014
Akorn, Inc. has completed its acquisition of VPI Holdings Corp., the parent company of VersaPharm Inc., for $440 million, expanding its presence in the dermatology market. The transaction is expected to add $90 to $100 million in annual revenues. 
"We are excited to announce that we have completed the acquisition of VersaPharm," said Raj Rai, chief executive officer of Akorn. "This highly strategic acquisition further strengthens our niche portfolio and accelerates our long-term growth opportunities."

blog comments powered by Disqus

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On